Filings

2 documents · 8 matches

1. VVOS Vivos Therapeutics, Inc. 10-K 2026-04-15

   Item 1A. Risk Factors.

   material weakness in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies
   7 matches in this document Show context Copy citation

2. VVOS Vivos Therapeutics, Inc. 8-K 2026-08-03

   Item 1.01. Entry into a Material Definitive Agreement.

   material weakness remediation, SEC comment letter response, audit management and capital markets readiness. From May 2026 to June 2026, through
   1 match in this document Show context Copy citation